Mineralys Therapeutics, Inc.(MLYS)
$15.33-0.17 (-1.10%)
MLYS
Mineralys Therapeutics, Inc. stock drug pipeline
$15.33
At close:-0.17 (-1.10%)
Want to see MLYS full AI Analyst Report?
Mineralys Therapeutics, Inc. (MLYS) Drug Pipeline
614 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Lorundrostat | Hypertension, Obstructive Sleep Apnea | Phase II | Active Not Recruiting | A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension | Jan 16, 2025 | ― |
| Lorundrostat Dose 1, Lorundrostat Dose 2 | Hypertension | Phase III | Completed | Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension | Nov 17, 2023 | ― |
| Lorundrostat | Hypertension | Phase III | Active Not Recruiting | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | Jul 14, 2023 | ― |
| Lorundrostat Dose 1, Lorundrostat Dose 2 | Hypertension | Phase II | Completed | A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen | Feb 24, 2023 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Lorundrostat | Phase II | Hypertension, Obstructive Sleep Apnea | Active Not Recruiting | A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension | Jan 16, 2025 | ― |
| Lorundrostat Dose 1, Lorundrostat Dose 2 | Phase III | Hypertension | Completed | Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension | Nov 17, 2023 | ― |
| Lorundrostat | Phase III | Hypertension | Active Not Recruiting | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | Jul 14, 2023 | ― |
| Lorundrostat Dose 1, Lorundrostat Dose 2 | Phase II | Hypertension | Completed | A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen | Feb 24, 2023 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Mineralys Therapeutics, Inc. (MLYS) have in its pipeline
Mineralys Therapeutics, Inc. MLYS is currently developing the following drugs: Lorundrostat, Lorundrostat Dose 1, Lorundrostat Dose 2. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

